国发股份(600538) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥101,579,609.22, representing a decrease of 15.94% compared to the same period last year[3] - The net profit attributable to shareholders of the listed company was -¥2,646,847.55, a decline of 135.74% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥3,089,888.09, down 144.02% from the previous year[3] - The basic earnings per share were -¥0.005, reflecting a decrease of 150.00% compared to the same period last year[3] - Net profit for Q1 2023 was a loss of ¥2,122,373.30, compared to a profit of ¥8,064,707.43 in Q1 2022, representing a significant decline[19] - The total comprehensive income attributable to the parent company was -2,646,847.55 CNY, compared to 7,406,463.37 CNY in the previous year[21] - The total comprehensive income for the period was -2,122,373.30 CNY, compared to 8,064,707.43 CNY in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,137,985,078.15, a decrease of 0.36% from the end of the previous year[4] - The company's total assets as of the end of Q1 2023 were ¥1,137,985,078.15, slightly down from ¥1,142,144,892.25 at the end of Q1 2022[17] - Total liabilities decreased to ¥180,127,941.32 in Q1 2023 from ¥182,165,382.12 in Q1 2022[17] - The total equity attributable to shareholders was ¥948,917,777.86 as of the end of Q1 2023, down from ¥951,564,625.41 in Q1 2022[17] Cash Flow - The company reported a net cash flow from operating activities of -¥29,405,928.68, which is not applicable for year-on-year comparison[3] - The net cash flow from operating activities was -29,405,928.68 CNY, a decline from -20,497,876.54 CNY year-over-year[21] - Cash inflow from operating activities totaled 85,107,320.59 CNY, down from 93,457,528.34 CNY in the same quarter last year[21] - The company’s cash and cash equivalents decreased from RMB 170,858,268.06 at the end of 2022 to RMB 147,578,019.16 as of March 31, 2023, representing a decline of approximately 13.6%[15] - Cash and cash equivalents at the end of the period were 126,184,836.92 CNY, down from 161,951,203.59 CNY at the end of the previous year[22] - The company received 10,000,000.00 CNY from investment recoveries during the quarter[22] - Total cash inflow from financing activities was 1,800,000.00 CNY, compared to 1,700,000.00 CNY in the previous year[22] - The company paid 366,127.64 CNY in cash outflows related to financing activities, down from 795,737.35 CNY year-over-year[22] Investments and Expenses - The company's investment in the Nanjing Huada Gongying No. 1 Venture Capital Partnership resulted in a loss increase of ¥3,665,800 due to the decline in stock prices of its listed projects[5] - The full subsidiary, Guangzhou Gaosheng Biotechnology Co., Ltd., experienced a decrease in executable contract amounts and gross profit margins, leading to a profit reduction of ¥5,974,500[6] - Research and development expenses for Q1 2023 were ¥1,664,937.32, an increase from ¥1,545,822.43 in Q1 2022[19] - The company reported an investment loss of ¥6,297,784.29 in Q1 2023, compared to a loss of ¥2,495,849.45 in Q1 2022[19] Shareholder Information - Shareholder Pan Libin has reduced his holdings by 665,100 shares, with a total reduction plan of up to 2.58 million shares[12] - The company’s major shareholders, Zhu Rongjuan and Peng Tao, hold a combined total of 107,673,242 shares, representing 20.55% of the total share capital, which are currently under judicial freeze[13] Strategic Plans - The company is enhancing market promotion and increasing internal discussions to adapt to new economic conditions, resulting in higher expenses[6] - The company plans to continue expanding its market presence and product offerings through strategic investments and partnerships[11] - The company's management indicated a focus on cost control and efficiency improvements in future operations[20]